CHIMENTI, SERGIO
 Distribuzione geografica
Continente #
NA - Nord America 45.804
AS - Asia 5.201
EU - Europa 4.976
SA - Sud America 753
AF - Africa 125
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 23
Totale 56.931
Nazione #
US - Stati Uniti d'America 45.628
SG - Singapore 2.279
CN - Cina 1.404
DE - Germania 826
UA - Ucraina 779
BR - Brasile 656
IT - Italia 607
HK - Hong Kong 499
IE - Irlanda 478
SE - Svezia 433
GB - Regno Unito 380
FR - Francia 359
RU - Federazione Russa 336
FI - Finlandia 186
PL - Polonia 185
VN - Vietnam 183
KR - Corea 180
IN - India 135
CA - Canada 121
TR - Turchia 69
NL - Olanda 66
JP - Giappone 64
ES - Italia 62
PK - Pakistan 51
BE - Belgio 50
ID - Indonesia 50
AU - Australia 45
CH - Svizzera 41
AR - Argentina 39
MX - Messico 39
EG - Egitto 36
ZA - Sudafrica 33
IR - Iran 29
BD - Bangladesh 28
IQ - Iraq 26
TW - Taiwan 26
RO - Romania 25
UZ - Uzbekistan 24
AT - Austria 23
KG - Kirghizistan 22
PH - Filippine 20
EU - Europa 19
HU - Ungheria 17
IL - Israele 17
AE - Emirati Arabi Uniti 16
GR - Grecia 16
EC - Ecuador 15
LT - Lituania 15
SK - Slovacchia (Repubblica Slovacca) 15
CZ - Repubblica Ceca 14
MA - Marocco 14
PT - Portogallo 14
MY - Malesia 13
CL - Cile 11
NG - Nigeria 11
CO - Colombia 10
EE - Estonia 10
SA - Arabia Saudita 10
JO - Giordania 9
OM - Oman 8
PE - Perù 8
RS - Serbia 8
DK - Danimarca 7
DZ - Algeria 7
HR - Croazia 7
TH - Thailandia 7
LB - Libano 6
PY - Paraguay 6
LV - Lettonia 5
NO - Norvegia 5
NP - Nepal 5
TN - Tunisia 5
VE - Venezuela 5
BJ - Benin 4
ET - Etiopia 4
KZ - Kazakistan 4
NZ - Nuova Zelanda 4
AZ - Azerbaigian 3
BH - Bahrain 3
DO - Repubblica Dominicana 3
GH - Ghana 3
JM - Giamaica 3
KW - Kuwait 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
CY - Cipro 2
HN - Honduras 2
KE - Kenya 2
MD - Moldavia 2
NI - Nicaragua 2
SN - Senegal 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
A1 - Anonimo 1
AD - Andorra 1
AL - Albania 1
AM - Armenia 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
Totale 56.918
Città #
Woodbridge 13.783
Wilmington 10.831
Houston 9.455
Fairfield 1.598
Ann Arbor 1.274
Chandler 1.064
Singapore 986
Ashburn 945
Jacksonville 683
Seattle 673
Cambridge 566
Beijing 553
Dublin 475
Hong Kong 468
Medford 386
Dearborn 290
Zhengzhou 265
New York 256
Santa Clara 203
The Dalles 186
Lawrence 182
Los Angeles 150
Kraków 137
Rome 133
Dallas 123
San Diego 97
Mülheim 87
Menlo Park 86
Shanghai 86
Buffalo 85
Munich 83
Boardman 72
São Paulo 68
Moscow 67
Redwood City 62
Council Bluffs 58
Hanoi 53
Milan 48
London 46
Redondo Beach 42
Toronto 40
Hefei 39
Ho Chi Minh City 39
San Mateo 39
Stockholm 37
Guangzhou 36
Nanjing 35
Tokyo 34
Brooklyn 32
Norwalk 32
Warsaw 31
Brussels 29
Montreal 29
Jakarta 28
Jönköping 28
University Park 28
Chicago 24
Falls Church 24
Verona 24
Nuremberg 23
Ankara 22
Madrid 22
Hangzhou 21
Kunming 21
San Francisco 21
Columbus 20
Denver 20
Mountain View 20
Palo Alto 20
Phoenix 20
Nanchang 19
Belo Horizonte 18
Dong Ket 18
Turin 18
Auburn Hills 17
Helsinki 17
Frankfurt am Main 16
Johannesburg 16
Poplar 15
Rio de Janeiro 15
Curitiba 14
Duncan 14
Atlanta 13
Chennai 13
Fuzhou 13
Redmond 13
Campinas 12
Detroit 12
Dubai 12
Mexico City 12
Utrecht 12
Lahore 11
Melbourne 11
Mumbai 11
Ottawa 11
Seoul 11
Baghdad 10
Budapest 10
Cairo 10
Central 10
Totale 47.947
Nome #
European S3-guidelines on the systemic treatment of psoriasis vulgaris 1.558
Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study 1.202
Atopic dermatitis and dental manifestations 525
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 511
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 505
Alopecia areata e trachionichia associato a sindrome da insufficienza endocrina plurighiandolare. 491
Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia 488
Inflammatory linear verrucous epidermal nevus and epilepsy: remission during valproic acid therapy 484
Clinical aspects of the oral cavity in patients with psoriasis: an initial study and a proposal of a new evaluation method 473
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis 470
Exclusion of CARD15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population 467
Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients 465
Effects of TNF-α and IL-1 β on the activation of genes related to inflammatory, immune responses and cell death in immortalized human HaCat keratinocytes 464
-174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers 464
IL-21 Promotes Skin Recruitment of CD4+ Cells and Drives IFN- -Dependent Epidermal Hyperplasia 459
Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study 458
Topical lactoferrin can improve stable psoriatic plaque 454
Apremilast for the treatment of psoriasis. 453
Tazarotene 0-1% gel for psoriasis of the fingernails and toenails: an open, prospective study [9] 447
New topical treatments for psoriasis 447
Treatment of trachyonychia with tazarotene 445
Successful treatment of multiple filiform facial warts with imiquimod 5% cream in a patient infected by human immunodeficiency virus 443
Psoriasis, kaposi's sarcoma and hodgkin's disease in a patient with down's syndrome [2] 443
Tazarotene as alternative topical treatment for onychomycosis 443
Combination of low-dosage cyclosporine and topical pimecrolimus in severe atopic dermatitis with chronic hepatitis B [10] 441
Actinic keratosis treated with an immune response modifier: a case report of six patients 439
Experimental T cells immunotherapy by tumor-loaded ECP-generated dendritic antigen presenting cells 433
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 431
Lung nodule and facial erythematous plaques: a quiz 431
Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis 430
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 429
Trimethoprim-sulfamethoxazole induced erythrodermic psoriasis 427
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 427
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 426
Alopecia areata e trachionichia associato a sindrome da insufficienza indocrina plurighiandolare 426
Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target 424
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 423
The significance of the development of antinuclear antibodies during infliximab treatment 423
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 422
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 421
Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population 419
Phrynoderma: a cutaneous sign of an inadequate diet 418
Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports 418
Diagnosis of pigmented skin lesions by dermoscopy: web-based training improves diagnostic performance of non-experts 415
Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases 414
Chronic mucocutaneous candidiasis and alopecia areata as cutaneous expressions of autoimmune polyglandular syndrome type I 413
Reply to Scalone and Cortesi: ‘‘Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate QALYs’’ 413
Infliximab therapy induces increased polyclonality of CD4+CD25+ regulatory T cells in psoriasis. 411
Remission and time of resolution of nail psoriasis during infliximab therapy [27] 409
Severe acne successfully treated with etanercept 408
Characterization of the loricrin (LOR) gene as a positional candidate for the PSORS4 psoriasis susceptibility locus 406
Local treatment of chronic cutaneous leg ulcers with recombinant human granulocyte-macrophage colony-stimulating factor. 406
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. 405
The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice 403
Treatment of lentigo maligna with tazarotene 0.1% gel 402
Bullous dermatomyositis: A marker of poor prognosis and aggressive internal malignancy? 401
Topical use of calcitriol 3 microg/g ointment in the treatment of mild-to-moderate psoriasis: results from an open-label study 401
Oral lichen planus: Novel acquisitions in the pathogenesis and treatment 401
Stress reactivity in psoriatic patients 400
Co-localization of susceptibility loci for psoriasis (PSORS4) and atopic dermatitis (ATOD2) on human chromosome 1q21 400
PSORS2 markers are not associated with psoriatic arthritis in the Italian population 400
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study 398
High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients' quality of life 397
Melanoma-associated markers expression in blood: MUC-18 is associated with advanced stages in melanoma patients 396
Cerebriform plantar hyperplasia: the clinico-pathological hallmark of Proteus syndrome 396
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers 392
Bowenoid papulosis and invasive Bowen's disease: a multidisciplinary approach 392
Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face 388
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody 388
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis 388
The tumor suppressor activity of IKK alpha in stratified epithelia is exerted in part via the TGF-beta anti proliferative pathway 387
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 387
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment 383
Localized morphea treated with imiquimod 5% and dermoscopic assessment of effectiveness 382
Prevention of Dermatologic Side Effects of Bimatoprost 0.03% Topical Therapy 380
A 2-year history of an asymptomatic scalp nodule - Cutaneous metastasis from renal cell carcinoma. 380
TNF-α antagonists and nail psoriasis: An open, 24-week, prospective cohort study in adult patients with psoriasis 378
Erysipeloid cutaneous metastasis from bladder carcinoma 375
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk 375
Tofacitinib for the treatment of psoriasis 374
Zosteriform metastasis of occult bronchogenic carcinoma 372
The first skin cancer screening day at the Italian parliament: A Euromelanoma initiative 372
Influence and variation of the body mass index in patients treated with etancercept for psoriasis 372
Chronically Sun-damaged Melanomas Express Low Levels of Nuclear Glutathione-S-transferase-π: An Epidemiological and Clinicopathological Study in Italy 372
Cyclosporine: a novel therapeutic approach for Burning Mouth Syndrome 367
Analysis of risk factors in cutaneous malignant melanoma: an italian population-based study 365
Immunologic biomarkers for clinical and therapeutic management of psoriasis 365
Severe erytrodermic psoriasis in child twins: From clinical-pathological diagnosis to treatment of choice through genetic analyses: Two case reports 365
Pyoderma vegetans and ulcerative colitis 364
Disseminated pagetoid reticulosis presenting as cytotoxic CD4/CD8 double negative cutaneous T-cell lymphoma 363
HIV-associated primary cutaneous anaplastic large cell lymphoma: A clinicopathological subset with more aggressive behavior? Case report and review of the literature 363
Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene 360
Ichthyosiform mycosis fungoides: A neoplastic acquired ichthyosis [5] 359
Metastatic Crohn's disease of the forehead 359
Cerebral cavernomas in a family with multiple cutaneous and uterine leiomyomas associated with a new mutation in the fumarate hydratase gene J Invest Dermatol. 2007 Sep;127(9):2271-3. 358
From patients’ needs to treatment outcomes in psoriasis: Results from the ‘pSORRIDI’ experience 358
Dermatitis artefacta in sporadic sclerodermoid hepatitis C virus-associated porphyria cutanea tarda 357
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 356
Green sweating spots on hands and feet: unusual expression of hyperbilirubinemia 351
Graham Little-Piccardi-Lassueur syndrome: effective treatment with cyclosporin A 350
Totale 43.059
Categoria #
all - tutte 132.838
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.838


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.247 0 0 0 0 0 662 786 688 312 238 407 154
2021/20222.147 86 274 151 138 59 177 103 114 146 185 141 573
2022/20232.776 259 230 141 408 234 583 182 155 286 27 169 102
2023/20241.154 119 52 81 50 104 290 81 106 23 38 25 185
2024/20254.235 176 811 437 262 113 240 382 210 349 330 479 446
2025/20262.946 561 331 810 605 566 73 0 0 0 0 0 0
Totale 57.726